Type-2 Biomarkers, Asthma Diagnosis and Lung Function Impairment in the General Population - Online supplement
Abstract
This is the online supplement to the manuscript titled Type-2 Biomarkers, Asthma Diagnosis and Lung Function Impairment in the General Population. It contains the full baseline characteristics of the study population (filename Table_1_full.pdf), results of multivariable regression adjusted for demographic and clinical covariates (OR_plot_EOS_FeNO_final.jpeg) and FEV1 % predicted by levels of blood eosinophils and FeNO in non-asthmatics (FEV1_plot_EOS_FeNO_final.png).
Full text
Table 1: NHANES 2007-2012 characteristics of the total study population, and stratified by asthma diagnosis Overall Population Asthmatics Non-asthmatic controls p N=18,319 N=1,584 (8.6%) N=16,735 (91,4%) Age (years), mean (SD) Children (<18) (n, %) Adults (18–65) (n, %) Elderly (>65) (n, %) 36.3 (20.9) 4825 (26.3) 11556 (63.1) 1938 (10.6) 32.7 (20.8) 6998 (57.7) 3009 (24.8) 2116 (17.5) 36.7 (20.8) 11823 (38.8) 14565 (47.8) 4054 (13.3) <0.001 Female, n (%) 8954 (48.9%) 891 (56.2%) 8063 (48.2%) <0.001 BMI (kg/m2), mean (SD) 26.9 (7.4) 28.1 (8.7) 26.8 (7.2) <0.001 Ethnicity, n (%) Mexican American Other Hispanic Non-Hispanic White Non-Hispanic Black Other Race - Including Multi-Racial 3357 (18.3%) 2014 (11.0%) 7322 (40.0%) 4006 (21.9%) 1620 (8.8%) 161 (10.2%) 182 (11.5%) 655 (41.4%) 466 (29.4%) 120 (7.6%) 3196 (19.1%) 1832 (10.9%) 6667 (39.8%) 3540 (21.2%) 1500 (9.0%) <0.001 Medication ICS use (n, %) ICS/LABA use (n, %) OCS use (n, %) OCS/ICS use in last 2 days (n, %) 408 (2.2%) 239 (1.3%) 183 (1.0%) 724 (4.0%) 344 (21.8%) 202 (12.8%) 57 (3.6%) 481 (30.4%) 64 (0.4%) 37 (0.2%) 126 (0.8%) 243 (1.5%) <0.001 <0.001 <0.001 <0.001 Smoking history Never smokers (n, %) Ex-Smokers (n, %) Current Smokers (n, %) 12431 (67.9%) 2959 (16.2%) 2929 (16.0%) 1081 (68.2%) 236 (14.9%) 267 (16.9%) 11350 (67.8%) 2723 (16.3%) 2662 (15.9%) 0.273 Spirometry Baseline FEV1 (L), mean (SD) Baseline FEV1pp, median (IQR)# Baseline FEV1/FVC, mean (SD) 2.87 (0.92) 89.7 (76, 100) 0.81 (0.1) 2.78 (0.95) 80.7 (67, 93) 0.78 (0.1) 2.88 (0.92) 90.4 (77, 101) 0.81 (0.1) 0.163 <0.001 <0.001 Type-2 biomarkers FeNO, mean ppb (SD) BEC, mean cells/μL (SD) 13 (8-20) 211 (190) 15 (8.5-28.5) 280 (230) 12.5 (8-20) 210 (190) <0.001 <0.001 Abbreviations: SD: Standard Deviation, BMI: Body Mass Index, ICS: Inhaled Corticosteroids, LABA: LongActing Beta-2 Agonists, OCS: Oral Corticosteroids, FEV1: Forced Expiratory Volume in 1 second, FEV1pp: percent of predicted Forced Expiratory Volume in 1 second, FVC: Forced Vital Capacity, FeNO: Fractional Exhaled Nitric Oxide, BEC: Blood Eosinophil Counts, statistically significant differences between asthmatics and participants without asthma are highlighted in bold. #FEV1 percent of predicted values were calculated using the Hankinson-formula